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InﬂammationMetastasis remains the major driver of mortality in patients with cancer. The multistep metastatic process re-
quires the concerted actions of several genes and involves tumor cell invasion, epithelialmesenchymal transition
(EMT), shedding from primary tumor, intravasation, arrest, extravasation and colonization at a preferential site.
Understanding this complex process would provide the basis for the development of molecularly targeted ther-
apeutics aimed at the tumor cell or its interaction with the hostmicroenvironment. The neuropeptide hormones
endothelins (specially, ET-1) have been correlated with invasiveness and metastasis of several cancers and high
ET-1 levels are associated with decreased disease-speciﬁc survival. The mechanism(s) by which ET-1 promotes
metastasis are being gradually unraveled. Throughpreferential binding to cognate receptors (ETAR or ETBR), ET-1
triggers autocrine and paracrine signaling cascades in tumor, immune and stromal cells, at both primary and dis-
tant sites, supporting cancer progression andmetastasis. In this review, wewill summarize the role of the ET axis
in metastasis of different cancers and potential targeting of ET receptors in the therapeutic setting.
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ET-1, an endothelial cell-derived vasoconstrictor peptide, is an im-
portant member of the endothelin axis with myriad developmental,ery and Pharmacology and
Aurora, Colorado 80045, USA.
Theodorescu).
Y-NC-ND license.physiological and pathological functions (Kedzierski and Yanagisawa,
2001; Herrmann et al., 2009, 2007; Hagemann et al., 2007). The
“endothelin axis” consists of three similar small peptides, ET-1, ET-2 and
ET-3, two G-protein-coupled receptors, ETAR and ETBR, and two
membrane-bound proteases, the ET-converting enzymes, ECE-1 and
ECE-2 (Kedzierski and Yanagisawa, 2001), that activate the secreted pro
forms of the peptide. ET-1 production is stimulated by a variety of
cytokines and growth factors, hypoxia, and shear stress, while ETAR
activation triggers signaling networks involved in cell proliferation,
new vessel formation, invasion, inﬂammation and metastatic spread
523N. Said, D. Theodorescu / Life Sciences 91 (2012) 522–527(Kedzierski and Yanagisawa, 2001; Bagnato et al., 2005; Giaid et al.,
1990; Rosano et al., 2003, 2007a). ET-1 has been shown to activate the
pro-inﬂammatory transcriptional factors AP-1 and NFκB in human
monocytes and cancer cells and to stimulate the production of inﬂam-
matory cytokines IL-6, CCL2/MCP-1 and COX2, as well as matrix metal-
loproteinases (MMPs) activity, the key orchestrators of inﬂammation-
mediated cancer cell invasiveness and metastasis (Kandalaft et al.,
2009; Sutcliffe et al., 2009; Spinella et al., 2004a, 2004b). Moreover, el-
evated expression of ECE-1, ET-1 and its receptors have been detected
in a variety of malignancies including prostate, ovarian, breast, melano-
ma, HNSCC, colorectal and bladder cancers (summarized in Bagnato et
al. (2011)). In addition to their direct contribution to tumor growth
and metastasis, members of the endothelin axis indirectly modulate
tumor–host interactions in various milieus' furthering tumor progres-
sion andmetastasis. For example, ET-1 promotes autocrine/paracrine in-
teractions between ﬁbroblasts and cancer cells in prostate and HNSCC
cells (Dawson et al., 2004) andmodulates trafﬁcking, differentiation,
and activation of tumor-associated immune cells, possibly contribut-
ing to immune evasion and resistance to immunotherapy (Kandalaft
et al., 2009; Grimshaw et al., 2002; Buckanovich et al., 2008; Said et
al., 2011). ET-1 can induce expression of IL-6, CCL-2, as well as MMP
and COX-2 activity, key orchestrators of inﬂammation-mediated cancer
cell invasiveness and metastasis via AP-1 and NF-κB (Rosano et al.,
2007a, 2001, 2007b; Sutcliffe et al., 2009; Grimshaw et al., 2002, 2004;
Said et al., 2011; Browatzki et al., 2007; Spinella et al., 2007). Recently,
we reported that tumor ET-1 triggers inﬂammation in the lung soon
after the cancer cells lodged at this site and thus sets up a vicious
cycle wherein inﬂammatory cells would enhance and facilitate the pro-
cess of metastatic colonization (Said et al., 2011) (Fig. 1).
Ovarian cancer
Ovarian cancer arises from the surface of the ovary. Hence cancer
cells shed from the primary tumor can disseminate as ﬂoating singleMigrat
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Fig. 1. Tumor cell colonization, survival, proliferation, invasion, angiogenesis, metastasis. D
• In tumor cells: Binding of ET-1 to the ETAR triggers multiple signal-transduction pathw
secretion of cytokines and growth factors IL-6, CCL2 (MCP-1), and VEGF as well as in
• In macrophages: ET-1 induces macrophage chemotaxis through ETAR and ETBR. Bindi
NFκB and AP-1 activation with subsequent induction of IL-6, CCL2, VEGF, EGF, TGFβ,
colonization in preferential metastatic sites.
• In endothelial cells and vascular smooth muscle cells: ET-1 stimulates endothelial an
receptor.cells or spheroids in the peritoneal ﬂuid and lead to implants on the
mesothelial lining of the peritoneal cavity or deeply penetrate the
omentum. In the ovarian cancer microenvironment, high ET-1 levels
were detected in the peritoneal ﬂuid in patients with malignant ascites
(Bagnato et al., 2005). In vivo analysis of the ET-1 axis demonstrated a
higher expression of ET-1 and ETAR in primary and metastatic tumors
than in normal ovarian tissues. Interestingly, ET-1-producing cells also
expressed functional ETAR, but not ETBR, indicating that in ovarian
tumor cells, ET-1 likely acts as an autocrine factor selectively through
the ETAR (Bagnato et al., 2005). In human ovarian tumors, ET-1 axis
overexpression is associatedwith ascites formation,malignant progres-
sion, advanced tumor stage, and enhanced tumor angiogenesis
(Bagnato et al., 1999, 2005). Here the ET-1/ETAR axis drives multiple
signaling networks involving epidermal growth factor receptors, integ-
rins,Wnt, andMMPs (Bagnato and Rosano, 2007) that regulate cell sur-
vival, invasiveness, angiogenesis, vascular permeability and EMT
(Rosano et al., 2010). ET-1 axis has been shown to be regulated by
and induce activation of hypoxia-inducible factor 1α (HIF-1α) and
EMT transcription factors as β-catenin/TCF, SNAIL and SLUG, suggesting
that the ET-1 axis contributes to the complex cooperation between the
intracellular signaling pathways and extracellular signals triggering
EMT (Bagnato et al., 2005; Spinella et al., 2004a, 2004b, 2007; Rosano
et al., 2001, 2007b, 2010; Bagnato and Rosano, 2007). Genome-wide ex-
pression proﬁling of ovarian carcinoma identiﬁed ETAR as a key gene re-
lated to chemoresistance (Rosano et al., 2010). Interestingly, paclitaxel
and platinum resistant ovarian cancer cells showed phenotypic changes
consistent with EMT, providing strong evidence linking ETAR signaling
pathways to chemoresistance, EMT and stemness of ovarian cancer
cells (Rosano et al., 2010).
In ovarian cancer, ETBR has been recently shown to control T-cell
homing to tumors and failure of immunotherapy as vaccine failure
was associated with poor accumulation of T cells at the tumor site, in
spite of detectable systemic antitumor immune response. ETBR block-
ade with speciﬁc antagonist BQ-788 greatly enhanced the efﬁcacy ofET-1 
ET-2 
ion/chemotaxis 
EGF, IL-6, CCL2, VEGF, TGFβ
ET1-inducing cytokines/ chemokines 
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ifferential roles of endothelin axis in the tumor microenvironment:
ays, leading to cell survival and invasion. ET-1 increases its own secretion as well as the
ﬂammatory mediators COX2 and prostaglandins-E2 (PGE-2).
ng of ET-1 to both receptors in macrophages triggers signaling pathways converging in
MMPs and COX2, subsequently, stimulating tumor cell invasiveness, recruitment and
d VSMCs proliferation, angiogenesis and vasculogenesis through interaction with ETAR
524 N. Said, D. Theodorescu / Life Sciences 91 (2012) 522–527vaccines in both preventing recurrence and therapy directed at estab-
lished tumors. BQ-788 did not increase systemic immune response to
the vaccine in vivo, but rather greatly enhanced T-cell inﬁltration in tu-
mors following vaccine (Kandalaft et al., 2009). Activation of a paracrine
ET-1/ETBR axis was also found between tumor cells and endothelial
cells, whereby tumor cells overexpress and release ET-1 whereas the
latter express ETBR. This axis suppresses T-cell homing (even in the
presence of tumor inﬂammation), and can be disrupted by ETBR block-
ade, which in vivo markedly enhances tumor immune therapy
(Kandalaft et al., 2009). ETBR blockade is likely to have also direct antian-
giogenic effects through suppression of endothelial nitric oxide. Interest-
ingly, ETBR upregulation predicts poor outcome in ovarian cancer
(Buckanovich et al., 2008).Bladder cancer
Gene expression data from several independent studies of human
bladder cancer have revealed that ET1 and ETAR were overexpressed
in muscle invasive disease and that the degree of expression is asso-
ciated with reduced patient survival (Said et al., 2011). This was con-
ﬁrmed at the protein level by ET-1 immunohistochemistry in human
bladder cancer tissue microarrays (Said et al., 2011). Interestingly, ET-
1 expression was positively correlated with the proinvasive and
proinﬂammatory mediators IL-6, CCL2, COX2 as well as MMP2 and
MMP9. However, an apparent paradox that has arisen in the ﬁeld re-
garding the role of ETAR in cancer is the ﬁnding that pharmacologic
blockade of this receptor has minimal effect on primary tumor
growth (Titus et al., 2005; Wulﬁng et al., 2005a, 2005b) yet affects ex-
perimental metastasis (Said et al., 2011; Titus et al., 2005) and that
clinical trials with ETAR inhibitors in patients with advanced cancers
appear to have minimal effect (Bagnato et al., 2011; Nelson et al.,
2008; Ohlmann et al., 2011; Clezardin, 2011; Nelson et al., 2011).
To decipher the role of ET-1/ETAR axis in bladder cancer metasta-
sis we used a comprehensive model whereby the endothelin axis, via
ETAR, was shown to drive bladder cancer lung colonization by regu-
lating key factors in the microenvironment of disseminated tumor
cells (Said et al., 2011). Using combined genetic and pharmacologic
approaches in human bladder cancer cell lines in vitro, we reported
the role of ET-1 in autocrine regulation of proliferation in bladder can-
cer cell lines and that ET-1 stimulates migration, invasion, and pro-
teolytic activity of such cells through ETAR. In vivo, using human
and murine models of experimental and spontaneous lung metasta-
sis, we showed that tumor ET-1 is a paracrine mediator of early
metastatic colonization of the lung through triggering an early in-
ﬂammatory response in the lung characterized by macrophage inﬂux,
and production of pro-inﬂammatory mediators MCP-1/CCL2, IL-6,
and COX-2. Interestingly, the IL-6, MCP-1/CCL2, COX-2, and MMPs in-
duced by ET-1 are also known to breach the lung vasculature and en-
able extravasation of cancer cells on dissemination of these cells to
the lungs (Qian et al., 2009; Gupta and Massague, 2006; Gupta et
al., 2007; Mantovani, 2009). This ET-1 or ETAR mediated early inﬂam-
matory response led to subsequent development of macroscopic lung
metastases. Interestingly, pharmacologic inhibition of ETAR by
ZD4054 prior to injection of tumor cells reduced the early inﬂamma-
tory response and subsequent development of lung metastases. In
contrast, when administration of ZD4054 was initiated after estab-
lishment of the early inﬂammatory response, the reduction in lung in-
ﬂammation and clinical lung metastases was less dramatic. We also
showed that the cellular effectors of this ET-1/ETAR axis are likely
macrophages since metastasis was suppressed by macrophage
depletion by liposomal clodronate nanoparticles. Given this data we
speculate that in clinical trials where pharmacologic inhibition of
ETAR did not affect primary tumor growth or established high-
volume metastatic disease, these tumors were no longer dependent
on macrophages for their maintenance or growth.Breast cancer
Elevated expression of ETAR in primary breast carcinoma is associated
with reduced disease-free survival time (Wulﬁng et al., 2003). ETAR-
positive carcinomas frequently show staining for ETAR in ﬁbroblasts
suggesting the existence of a paracrine axis since breast cancer cells ex-
press ET-1 (Wulﬁng et al., 2003; Kojima and Nihei, 1995). High ET-1/
ETAR-positive tumors were associatedwith clinicopathological markers
of aggressiveness and poor prognosis such as tumor size, poor differen-
tiation, high grade, Her-2/neu overexpression, lymphovascular inva-
sion, inﬂammation as well as with incidence of local recurrence or
distant metastasis (Wulﬁng et al., 2003). The above ﬁndings suggested
that ET-1 and ETAR may be useful prognostic biomarkers in breast car-
cinomas and may help to identify patients who may beneﬁt from adju-
vant therapy (Wulﬁng et al., 2003). Mechanistic studies revealed that
endothelins (1 and 2) induce breast cancer cell invasiveness through
HIF1α, inﬂammatory cytokines/chemokines, and MMPs (Grimshaw et
al., 2004; Grimshaw, 2005; Yamashita et al., 1995; Wilson et al., 2006;
Hagemann et al., 2005). ET-1 secretion in breast cancer cells is induced
by EGF via EGFR and HER2 and involves MAPK-dependent signaling. In
turn, an ET-1/ETAR-dependent regulation of EGFR protein expression
and phosphorylation (at Tyr845) was observed and conferred an addi-
tional anti-proliferative and anti-invasive effect to ETAR blocker atra-
sentan, in trastuzumab treated cells (Fischgrabe et al., 2010). ETAR
antagonism also has additive antitumor activity in breast cancer cells
treated with aromatase inhibitors in vitro and in vivo (Smollich et al.,
2010). ETAR blocker, ZD4045 was equipotent to aromatase inhibitors
and in combination, exerted an additive effect on in vitro cells and in
vivo in tumor xenografts (Smollich et al., 2010).
Recently, ET-1 was found to mediate the invasive properties of
triple-negative breast cancer (TNBC) (Ha et al., 2011) as a down-
stream effector of lactoferrin (Lf) which efﬁciently downregulates
levels of ER-alpha, PR, and HER-2 in a proteasome-dependent manner
(Ha et al., 2011)with subsequent loss of responsiveness of breast cancer
cells to ER- or HER-2-targeted therapies. Lactoferrin-induced increased
invasion of breast cancer cellswasmediated via transcriptional stimula-
tion of ET-1 and was effectively blocked by antagonists of the ET-1 re-
ceptor. Co-overexpression of lactoferrin and ET-1 in tumors as well as
elevated circulating levels was observed in serum from TNBC as com-
pared with samples from ER-, PR-, and HER-2-positive breast tumors.
Thus targeting Lf–ET-1 axis in TNBC represents a new promising
approach (Ha et al., 2011).
Prostate cancer
ET-1 plasma concentrations are elevated in men with metastatic
and hormone refractory prostate cancer compared to those with lo-
cally conﬁned disease or healthy control (Nelson et al., 1995). Immu-
nohistochemistry revealed that primary prostate cancers and prostate
cancer bone metastases were usually positive for ET-1 expression
(Nelson et al., 1995, 1996). Prostate cancers express higher ET-1
and ETAR but less ETBR than normal prostate tissue (Nelson et al.,
1996). The in vitro mitogenic effect of exogenous ET-1 on prostate
cancer cell lines is modest, but it enhances the effects of a variety of
growth factors such as basic ﬁbroblast growth factor b (bFGF),
insulin-like growth factor (IGF), and platelet-derived growth factor
(PDGF) (Nelson et al., 2003), and in conjunction with VEGF, plays a
major role in tumor angiogenesis. ET-1, through ETAR, transactivates
EGFR (Konety and Nelson, 2001), a ﬁnding that was veriﬁed in a re-
cent study by Wang et al. (2011). The ET-1/ETAR-EGFR pathway was
shown to activate the PI3K/AKT pathway, which is known to play an
important role in prostate cancer progression (Nelson et al., 2003).
ET-1 also activates focal adhesion kinase (FAK) and elevates intracel-
lular calcium in several prostate cancer cell lines (Dawson et al., 2004,
2006; Nelson et al., 2003). ET-1 expression is also associated with
the transition from androgen-dependent to androgen-independent
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produced by upregulation of ECE-1 in tumor associated stromal cells
(Dawson et al., 2004, 2006).
Colorectal cancer
Preoperative plasma big ET-1 concentration is a predictor of over-
all survival in patients with colorectal cancer suggesting its utility in
selecting high-risk, lymph node-negative patients for adjuvant therapy
(Elahi and Everson, 2004; Arun et al., 2002, 2004; Hoosein et al., 2007;
Lloyd et al., 2011). In another study, however, elevated serum ET-1
levels in patientswith colorectal cancer did not seem to be of prognostic
value for survival (Peeters et al., 2000). Immunohistochemistry and
immunoelectron microscopy demonstrated increased ET-1 expression
in colorectal cancer including endothelial and stromal cells within and
surrounding primary and liver metastases (Shankar et al., 1998;
Simpson et al., 2000). Patients with colorectal cancer with and without
liver metastases had elevated plasma levels of ET-1 (Elahi and Everson,
2004; Shankar et al., 1998). Portal vein chemotherapy with ETAR antag-
onist BQ123 in a rodent model (Elahi and Everson, 2004; Asham et al.,
2001) produced a signiﬁcant reduction in micrometastasis speciﬁcally
when given at the time of, but not after, tumor cell inoculation suggest-
ing the role of ET-1/ETAR in promoting tumor implantation and the
initial establishment of micrometastases (Asham et al., 2001). The
frequent overexpression of the ET-1 gene in human colon cancers was
reported to be a direct consequence of genetic alterations of β-catenin
signaling in these tumors as inactivating mutations in the APC gene or
activating mutations in β-catenin lead to the formation of β-catenin/
TCF4 complex on the ET-1 promoter, which in turn activates transcrip-
tion of the gene. ET-1 would contribute to β-catenin's oncogenic pro-
gram by providing antiapoptotic and growth-promoting functions
(Kim et al., 2004).
Head and neck cancer
Activation of the endothelin axis is a feature of head and neck
squamous cell carcinoma (HNSCC) (Hinsley et al., 2012). High pretreat-
ment levels of plasma big ET-1 levels were generally associated with
posttreatment distant failure in patients with advanced-stage nasopha-
ryngeal carcinoma, (NPC) (Hearnden et al., 2009; Wen et al., 2011).
ETAR was overexpressed in 74% of NPC and its expression was found
to be a robust independent determinant of survival and an independent
predictor of distant metastasis (Hinsley et al., 2012; Hearnden et al.,
2009). Awano et al. (2006) demonstrated that ET-1 is able to act in an
autocrine manner to stimulate the proliferation of HNSCC cells via
both, ETAR and ETBR. In this study, ET-1was able to stimulate themigra-
tion of HNSCC cells, an effect dramatically ampliﬁed by the presence of
oral ﬁbroblasts. This paracrine stimulation of HNSCC motility results
from the ET-1-stimulated proteolytic release of bioactive ligands from
ﬁbroblasts, mediated in part by ADAM17, transactivating EGFR on
HNSCC cells, triggering an increase in COX-2 expression (Hinsley
et al., 2012;Wenet al., 2011; Awano et al., 2006). Interestingly, ETAR an-
tagonist ABT-627 can inhibit the growth and metastasis of NPC cells
and increase sensitivity to chemotherapy (Mai et al., 2006). The
EDNRA/H323H polymorphism was found to be an independent prog-
nostic marker for overall survival in patients with locally advanced
NPC. Patients with EDNRA/H323H had poorer 5-year overall survival
compared to patients with wild-type genotype. The functional signiﬁ-
cance of this polymorphism has yet to be elucidated (Wen et al., 2011).
Melanoma
ET-1, ET-3 and ETBR are implicated in melanocyte transformation
and melanoma progression and ETBR is the major endothelin receptor
expressed by normal and transformed melanocytes (Spinella et al.,
2007). Gene expression proﬁling of human melanoma biopsies andcell lines indicated positive correlation of ETBR with aggressive pheno-
type (Imokawa et al., 1992). ET-1 was shown to be secreted by keratino-
cytes in response to UV, stimulating proliferation, chemotaxis, and
pigment production inmelanocytes, and promotingmelanocyte survival
and inhibiting the UV-induced apoptosis through the phosphatidylino-
sitol 3-kinase (PI3K)-Akt pathway (Hachiya et al., 2004; Kadekaro et al.,
2005). UV-induced ET-1 via ETBR down-regulates E-cadherin expres-
sion concomitant with increased expression of N-cadherin, MMP-2,
MMP-9, and αvβ3 and α2β1 integrins and inhibits intercellular commu-
nication by inducingphosphorylation of gap junctional protein connexin
43 (Spinella et al., 2007; Jamal and Schneider, 2002). In addition, ET-1/
ETBR upregulates melanoma cell adhesion molecule (MCAM), a marker
of melanoma aggressiveness and metastasis, in primary and metastatic
melanoma cell lines (Mangahas et al., 2004). In melanoma cell lines,
ET increases HIF-1αwith subsequent upregulation of vascular endothe-
lial growth factor (VEGF), COX-1/COX-2 expression and activity and
PGE2 production in normoxic and hypoxic conditions (Spinella et al.,
2007). COX-1/COX-2 inhibitors blocked ET-induced PGE2 and VEGF se-
cretion, MMP activation and cell invasion, indicating that both enzymes
function as downstreammediators of ET-1 induced invasive properties.
In melanoma xenografts, ETBR blockade suppressed HIF-1α accumula-
tion, tumor growth, neovascularization, VEGF expression and MMP-2
(Spinella et al., 2007). Moreover, ET-1 and -3 induced secretion of pro-
metastatic CXC chemokines (Mangahas et al., 2005) further implicating
the proinﬂammatory properties of ET-1 in melanoma invasiveness and
metastasis.
The endothelin axis in bone metastasis
In addition to the effects of ET-1 on tumor growth and invasiveness,
the paracrine effects of tumor-produced ET-1 on bone cellsmay create a
fertile growth environment for tumor cells in bone. In the bone micro-
environment, tumor-derived ET-1 stimulates mitogenesis in osteo-
blasts, which express both ETAR and ETBR, and it decreases osteoclast
activity and motility (Nelson et al., 2003), and therefore is involved in
the formation of osteoblastic lesions that are frequently observed in pa-
tients with metastatic prostate cancer and, to a lesser extent, in meta-
static breast cancer (Nelson et al., 2003). In preclinical models,
osteoblastic bonemetastases elicited by human andmurine breast can-
cer cell lines were inhibited by ETAR antagonist atrasentan (Guise et al.,
2003; Yin et al., 2003) and the mixed (ETAR and ETBR) inhibitor bosen-
tan (Dreau et al., 2006). The effect of the ETA receptor-selective antago-
nist ABT-627 to block ET-1-stimulated osteoblast proliferation and new
bone formation was speciﬁc because it did not block FGF-2-stimulated
new bone formation (Guise et al., 2003). In prostate cancer, ET-1
production was down-regulated by androgens and up-regulated by
the bone-associated factors transforming growth factor β (TGFβ), EGF,
IL-1-β, IL-1-α, and TNF-α (Le Brun et al., 1999). Co-cultures of prostate
cancer and bone have demonstrated that ET-1 production is increased
by prostate cancer cells in contact with bone (Chiao et al., 2000).
These effects are mediated via ETAR (Nelson et al., 1995, 1996).
Conclusion
The ET axis is deeply implicated in themalignant process and tumor
progression in several tumor types. In addition components of this axis
have potential as prognostic and predictive biomarkers. The pro-
metastatic effect of ET/ETRs in most cancers involves paracrine effects
regulating tumor-stromal interactions and involving pro-inﬂammatory
cytokines/chemokines, COX2 and the matrix metalloproteinase. Indeed
the identiﬁcation of endothelin and biomarkers associated with it
(Said et al., 2011) in primary tumors begets the design of clinical trials
with endothelin axis inhibitors either after radical surgery or in combi-
nationwith standard of care chemoor radiotherapy tohampermetastatic
seeding. Interestingly, despite signiﬁcant evidence for a role in cancer,
prostate cancer has been the only human tumorwhere signiﬁcant clinical
526 N. Said, D. Theodorescu / Life Sciences 91 (2012) 522–527studies have been undertaken to explore the beneﬁts of interrupting
the ET axis.
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